Copyright
©The Author(s) 2015.
World J Gastrointest Oncol. Apr 15, 2015; 7(4): 17-29
Published online Apr 15, 2015. doi: 10.4251/wjgo.v7.i4.17
Published online Apr 15, 2015. doi: 10.4251/wjgo.v7.i4.17
Treatment | Description | Physiologic benefit | Possible mechanism | Ref. |
Megestrol acetate | Active progesterone derivative | Improves appetite, caloric intake, nutritional status, quality of life | Unknown; possible neuropeptide Y release | [80-92] |
Medroxyprogesterone | Active progesterone derivative | Improves appetite, food intake Weight stabilization | Decreases serotonin, IL-1, IL-6, TNF-α | [93-96] |
Ghrelin | Gastric peptide hormone | Improves lean + total body mass, hand grip, cardiac function (CHF cachexia only) | Growth hormone receptor secretagogue | [105] |
Delta-9-tetrahydrocannabinol | Cannabinoid | MIXED May improve food intake, weight gain | Possible endorphin receptor activation, Inhibition of prostaglandin, IL-1 | [85,106-110] |
Melanocortin antagonists | Adrenocorticotropic hormone antagonist | UNTESTED; prevention of anorexia, loss of lean body mass or basal energy (animal only) | Neuropeptide Y alteration or melanocortin-4 receptor antagonism | [112,113] |
Thalidomide | Immunomodulatory | Limits weight and lean body mass loss | Decreases TNF-α, pro-inflammatory cytokines, nuclear factor kappa B, cyclooxygenase 2, angiogenesis | [124-126] |
Etanercept | Immunomodulatory | Limits fatigue; improves adjuvant therapy adherence | Decreases TNF effect | [127] |
Eicosapentaenoic acid/omega-3-fatty acids | Lipid | MIXED; may improve weight, appetite, quality of life | Decreases pro-inflammatory cytokines, proteolysis inducing factor | [129,130,133,137,140-142,146-152] |
Rikkun-shito | Herbal Japanese medicine | Improves median survival with gemcitabine (pancreatic cancer); improves anorexia, GI dysmotility, muscle wasting, anxiety | Unknown | [154,155] |
Corticosteroids | Immunomodulatory | Improves appetite and quality of life | Various mechanisms | [156,157] |
Formoterol | β2-adrenergic agonist | UNTESTED | Protein and muscle degradation antagonism | [170] |
Erythropoetin | Glycoprotein hormone | Improves patient’s metabolic and exercise capacity | Decreases production of IL-6 | [171-173] |
ACE inhibitors | Heart medications | Reduce wasting of muscle mass | Inhibit TNF-α production | [174] |
β-blockers | Heart medications | Preserved body weight, and lean and fat mass, and improved the quality of life | Normalized Akt phosphorylation | [175] |
- Citation: Aoyagi T, Terracina KP, Raza A, Matsubara H, Takabe K. Cancer cachexia, mechanism and treatment. World J Gastrointest Oncol 2015; 7(4): 17-29
- URL: https://www.wjgnet.com/1948-5204/full/v7/i4/17.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v7.i4.17